Overview

Evaluation of N1539 Following Major Surgery

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.
Phase:
Phase 3
Details
Lead Sponsor:
Recro Pharma, Inc.
Treatments:
Meloxicam